



26 February 2021

---

**Nigerian Equities | 2021 Corporate Action Calendar**

Stock	Proposed dividend (₦)	Bonus	Closure of Register	AGM Date	Payment Date
Lotus Halal Fixed Income Fund	<b>33.00</b>	Nil	21 <sup>st</sup> January 2021	NA	22 <sup>nd</sup> January 2021
Neimeth International Pharmaceutical Plc	<b>0.065</b>	Nil	23 <sup>rd</sup> February 2021	9 <sup>th</sup> March 2021	12 <sup>th</sup> March 2021
Vitafoam Nigeria Plc	<b>0.70</b>	Nil	15 <sup>th</sup> February 2021	4 <sup>th</sup> March 2021	5 <sup>th</sup> March 2021
Nigerian Breweries Plc	<b>0.69</b>	Nil	11 <sup>th</sup> – 17 <sup>th</sup> March 2021	22 <sup>nd</sup> April 2021	23 <sup>rd</sup> April 2021

---

Copyright © 2021 Asset & Resource Management Company Limited (“ARM”).

All rights reserved. Unauthorised use, reproduction, distribution or disclosure of this document is strictly prohibited.

This material has been issued by Asset & Resource Management Company Limited (“ARM”), a Company regulated by the Nigerian Securities and Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARM and its analysts believe to be reliable. Neither ARM nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party’s use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARM, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARM. By accepting this document, you agree to be bound by the foregoing limitations.